Interleukin 1 Beta (Il 1Β) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Inflammatory Cytokine |
| Target |
IL-1β |
| Sample Type |
CSF, Blood, Serum |
| Diseases |
AD, PD, ALS, HD, Stroke, TBI |
| Role |
Pro-inflammatory cytokine, innate immunity |
Interleukin-1 beta (IL-1β) is a key pro-inflammatory cytokine in the interleukin-1 family. It is produced primarily by activated microglia, astrocytes, and peripheral macrophages in response to infection, injury, or disease pathology. IL-1β plays a central role in neuroinflammation and has been implicated in the pathogenesis of virtually all neurodegenerative diseases.
¶ Structure and Function
IL-1β is synthesized as a 31 kDa pro-form that requires caspase-1 cleavage to generate the 17 kDa biologically active form. It signals through the IL-1 receptor type I (IL-1R1), which recruits the IL-1 receptor accessory protein (IL-1RAcP) to initiate downstream signaling.
- Pro-inflammatory signaling: Activates NF-κB and MAPK pathways
- Fever induction: Acts on hypothalamus to raise body temperature
- Glial activation: Induces astrocyte and microglial reactivity
- APP processing: Increases BACE1 expression and Aβ production
- Tau phosphorylation: Promotes GSK-3β activation
- Elevated CSF IL-1β in AD vs controls
- Correlates with disease severity and progression
- Associated with hippocampal atrophy
- May accelerate amyloid and tau pathology
- Increased CSF and blood IL-1β in PD patients
- Associated with motor symptom severity
- Linked to dopaminergic neuron loss
- May predict disease progression
- Elevated in CSF and serum of ALS patients
- Correlates with disease progression rate
- Associated with microglial activation
- Potential therapeutic target
- Increased IL-1β in striatum and CSF
- Contributes to excitotoxicity
- Associated with disease progression
- Mutant huntingtin enhances IL-1β production
| Method |
Sensitivity |
Clinical Use |
| ELISA |
pg/mL |
Research, clinical |
| Simoa |
fg/mL |
Ultra-sensitive detection |
| Meso Scale Discovery |
High |
Multiplex panels |
| Luminex |
High |
Cytokine panels |
Targeting IL-1β:
- Anakinra: IL-1 receptor antagonist, tested in AD
- Canakinumab: Anti-IL-1β antibody, clinical trials in AD
- Lodrgenumab: Anti-IL-1β antibody
- IL-1RA: Endogenous inhibitor, neuroprotective in models
| Disease |
CSF Level |
Correlation |
Prognostic Value |
| AD |
↑ Elevated |
Disease severity |
Moderate |
| PD |
↑ Elevated |
Motor scores |
Moderate |
| ALS |
↑ Elevated |
Progression rate |
High |
| HD |
↑ Elevated |
Disease stage |
Moderate |
| FTD |
↑ Elevated |
Disease severity |
Low |
The study of Interleukin 1 Beta (Il 1Β) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation. 2008;5:7. PMID:18302763
- Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001;22(6):903-908. PMID:11754997
- Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23(12):618-625. PMID:11102752
- Kitazawa M, Cheng D, Tsukamoto MR, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's model. J Immunol. 2011;187(12):6539-6549. PMID:22095734
- Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611-7615. PMID:2529544
- Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Exp Ther Med. 2016;11(3):811-818. PMID:26998007
- Liu S, Liu Y, Hao W, et al. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation. J Immunol. 2012;188(3):1098-1107. PMID:22184724
- Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463-477. PMID:24945771